PMID- 35347009
OWN - NLM
STAT- MEDLINE
DCOM- 20220404
LR  - 20231213
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 42
IP  - 4
DP  - 2022 Apr
TI  - Clinical Outcomes of Ramucirumab as Post-treatment Following 
      Atezolizumab/Bevacizumab Combination Therapy in Advanced Hepatocellular 
      Carcinoma.
PG  - 1905-1910
LID - 10.21873/anticanres.15667 [doi]
AB  - AIM: The present study evaluated the efficacy and safety of ramucirumab (RAM) in 
      clinical practice as post-treatment, following atezolizumab plus bevacizumab 
      (Atz/Bev) for advanced hepatocellular carcinoma (HCC) with alpha-fetoprotein 
      (AFP) levels of >/=400 ng/ml. PATIENTS AND METHODS: Of the 77 patients treated with 
      Atz/Bev at our institution, 13 patients for whom RAM was introduced as 
      post-treatment following Atz/Bev were enrolled in this retrospective study. There 
      were 9 patients (69.2%) with Child-Pugh A and 11 patients (84.6%) for whom RAM 
      was initiated as 3(rd)- or later-line therapy. The median AFP level was 2259 
      ng/ml. RESULTS: The objective response rate by Response Evaluation Criteria in 
      Solid Tumours at 6 weeks was 15.4%, and the disease control rate was 69.2%. The 
      median time to progression was 3.0 months; AFP level decreased at 2 weeks in 11 
      patients (84.6%) and at 6 weeks in seven patients (53.8%). The most common 
      adverse events (AEs) within 6 weeks were ascites, peripheral oedema, and 
      proteinuria, while grade 3 AEs occurred in six patients (46.2%). 
      Albumin-bilirubin scores at both 4 and 6 weeks were significantly worse than 
      those at baseline. CONCLUSION: In HCC patients with AFP levels of >/=400 ng/mL, RAM 
      after Atz/Bev is expected to be an effective treatment option. Careful attention 
      should be paid to the development of AEs and deterioration of liver function, 
      especially when RAM is used as 3(rd)- or later-line therapy. Additional studies 
      are needed to confirm the efficacy and safety of RAM as 2(nd)-line treatment 
      after Atz/Bev in Child-Pugh A patients.
CI  - Copyright (c) 2022 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Kuzuya, Teiji
AU  - Kuzuya T
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan; teiji.kuzuya@fujita-hu.ac.jp.
FAU - Kawabe, Naoto
AU  - Kawabe N
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Hashimoto, Senju
AU  - Hashimoto S
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Funasaka, Kohei
AU  - Funasaka K
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Nagasaka, Mitsuo
AU  - Nagasaka M
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Nakagawa, Yoshihito
AU  - Nakagawa Y
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Miyahara, Ryoji
AU  - Miyahara R
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Shibata, Tomoyuki
AU  - Shibata T
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
FAU - Takahara, Takeshi
AU  - Takahara T
AD  - Department of Surgery, Fujita Health University, Toyoake, Japan.
FAU - Kato, Yutaro
AU  - Kato Y
AD  - Department of Surgery, Fujita Health University, Toyoake, Japan.
FAU - Sugioka, Atsushi
AU  - Sugioka A
AD  - Department of Surgery, Fujita Health University, Toyoake, Japan.
FAU - Hirooka, Yoshiki
AU  - Hirooka Y
AD  - Department of Gastroenterology and Hepatology, Fujita Health University, Toyoake, 
      Japan.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - 52CMI0WC3Y (atezolizumab)
SB  - IM
MH  - Antibodies, Monoclonal, Humanized
MH  - Bevacizumab/adverse effects
MH  - *Carcinoma, Hepatocellular/drug therapy/pathology
MH  - Humans
MH  - *Liver Neoplasms/drug therapy/pathology
MH  - Retrospective Studies
MH  - Ramucirumab
OTO - NOTNLM
OT  - Alpha fetoprotein
OT  - atezolizumab plus bevacizumab
OT  - hepatocellular carcinoma
OT  - post-treatment
OT  - ramucirumab
EDAT- 2022/03/30 06:00
MHDA- 2022/04/05 06:00
CRDT- 2022/03/29 05:44
PHST- 2022/02/06 00:00 [received]
PHST- 2022/02/21 00:00 [revised]
PHST- 2022/02/22 00:00 [accepted]
PHST- 2022/03/29 05:44 [entrez]
PHST- 2022/03/30 06:00 [pubmed]
PHST- 2022/04/05 06:00 [medline]
AID - 42/4/1905 [pii]
AID - 10.21873/anticanres.15667 [doi]
PST - ppublish
SO  - Anticancer Res. 2022 Apr;42(4):1905-1910. doi: 10.21873/anticanres.15667.